Oncolytics Biotech, Inc.

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncolytics Biotech reports strong earnings and growth opportunities ahead

Oncolytics Biotech's Q4 2022 earnings call highlighted notable progress, strong financials, and promising trial outcomes.
The company faces challenges in trial design and collaboration agreements but is well-positioned for growth.
Opportunities lie in upcoming trial readouts, business development efforts, and expansion into Asian markets.

Oncolytics Biotech progresses in key trials, eyes market impact

Oncolytics Biotech, Inc. demonstrated progress in key trials and financial stability, positioning itself for potential market impact.
Strategic focus on validating data, understanding mechanisms of action, and pursuing efficient registration pathways underscores the company's commitment to innovation.
Challenges in managing trial outcomes and sustaining growth require careful navigation, but opportunities in diversification and market expansion offer avenues for success.
Overall, the company's emphasis on strategic milestones and licensing opportunities signals a proactive approach to maximizing value and market potential.

Oncolytics Biotech reports positive Q2 results and eyes growth opportunities

Oncolytics Biotech's Q2 2023 earnings call highlighted positive progress in clinical trials and strong financial performance.
The company's focus on research and development, business development efforts, and commitment to expansion present growth opportunities.
Challenges include trial execution concerns, complexities in combining treatments, and regulatory pathways that need to be navigated.

Oncolytics Biotech reports positive Q3 results and eyes strategic partnerships

Oncolytics Biotech demonstrated strong performance and promising outcomes in Q3 2023, with pela showing success in clinical trials for pancreatic and colorectal cancers.
While facing challenges in data clarity and market positioning, the company has opportunities to expand treatments, collaborations, and advance regulatory studies.
Overall, the company's financial stability, clinical progress, and strategic partnerships position it well for future growth and advancements in cancer treatments.

Oncolytics Biotech reports robust earnings, eyes oncology expansion in 2024

Oncolytics Biotech, Inc. showcased strong financial performance and progress in becoming a late-stage cancer company.
While facing challenges in research validation and managing operating costs, the company is well-positioned for growth.
Opportunities lie in validating survival benefits, expanding pela's market potential, and advancing strategic objectives in oncology.
Overall, Oncolytics' focus on innovation, financial prudence, and clinical advancements sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coda Octopus Group

Enel Chile

A handful of stocks to buy under $20 can offer investors explosive returns in uncertain market conditions. The article lists names that might not immediately grab headlines, but their strategic focus and innovative progressiveness qualify them as potential multi-baggers.

3 Under-$20 Stocks to Buy for Explosive Returns

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor Relations and Communications Matt Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Soumit Roy - JonesTrading John Newman - Canaccord Operator Good morning, and welcome to Oncolytics Biotech's Second Quarter 2023 Conference Call.

Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript

Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression Pelareorep selected for inclusion in the Precision PromiseSM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial $24.4 million in cash, cash equivalents and marketable securities as of June 30, 2023 provides projected runway into H2 2024 Strengthened financial position with a successful US$15 million public offering on August 8, 2023 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 14, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2023.

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights

SAN DIEGO and CALGARY, AB , Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at Canaccord Genuity's 43rd Annual Growth Conference, which is taking place August 7-10, 2023 at the InterContinental Boston in Boston, MA. Additional details on the fireside chat can be found below.

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference

Positive results achieved, in using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients, in the phase 2 BRACELET-1 study. Preparation is underway to initiate a phase 3 study using pelareorep + paclitaxel for the treatment of HR+/HER2- metastatic breast cancer patients. The global breast cancer market size is expected to reach $85.5 billion by 2032; About 74% of all breast cancer are both HR-positive and HER2-negative.

Oncolytics: Proof Of Concept In 2 Large Market Indications

The stock of Oncolytics Biotech Inc. ONCY, +23.25% soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreatic cancer clinical trial. An adaptive clinical trial is one which allows modifications to the trial or statistical procedures in the trial after it has been initiated.

Oncolytics Biotech's stock soars 25% after pelareorep is selected for inclusion in late-stage pancreatic cancer trial

Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study expected to support approval of pelareorep in combination with a checkpoint inhibitor, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic cancer Data presented at SITC 2022 showed a near tripling of overall response rate for pelareorep + gemcitabine + nab-paclitaxel + a PD-L1 inhibitor compared to historical control trials SAN DIEGO, CA and CALGARY, AB , June 22, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced pelareorep has been selected for inclusion as a new investigational treatment in Precision PromiseSM, an innovative adaptive Phase 3 clinical trial. The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel.

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5%  confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab Oncolytics' HR+/HER2- breast cancer program now phase 3-ready and advancing to a registrational study of pelareorep-paclitaxel combination Data to be discussed during a key opinion leader webinar today, June 5 th at 8:00 a.m.

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB , May 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer, which will be featured in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

31%  week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off date Updated data from May 2023 cut-off date will be presented in an oral presentation on June 3, 2023 Oncolytics to advance to registrational study of pelareorep-paclitaxel combination in HR+/HER2- breast cancer SAN DIEGO, and CALGARY, AB , May 25, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer.

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief Executive Officer Thomas Heineman – Chief Medical Officer Andrew de Guttadauro – Global Head of Business Development Kirk Look – Chief Financial Officer Conference Call Participants John Newman – Canaccord Louise Chen – Cantor Fitzgerald Patrick Trucchio – H.C. Wainwright Douglas Miehm – RBC Capital Markets Operator Good morning.

Oncolytics Biotech Inc. (ONCY) Q1 2023 Earnings Call Transcript

Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023 $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Calif.

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB , April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from June 2 – 6, 2023 in Chicago, Illinois and online. "Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "ASCO is widely recognized as one of the world's premier oncology conferences, and we're thrilled that our collaborators at PrECOG will have such a prestigious venue to present the randomized phase 2 BRACELET-1 trial.

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

SAN DIEGO and CALGARY, AB , March 28, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium, which is taking place April 3-5, 2023 in a virtual format. Additional details on the panel presentation can be found below.

Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor Relations and Communications Matt Coffey - Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head, Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2022 Conference Call.

Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Call Transcript

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for a randomized data readout in Q2 2023 that will inform the design of a pivotal trial Registration opportunities in breast and pancreatic cancer are supported by FDA Fast Track designations $32.1 million in cash, cash equivalents and marketable securities as of December 31, 2022 provides projected runway through BRACELET-1's upcoming readout and into 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, Alberta , March 3, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB , Dec. 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B.

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cance

Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?

FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

SAN DIEGO and CALGARY, AB , Nov. 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González Convention Center in San Antonio, Texas from December 6 – 10, 2022.

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reported in historical control trials Data support Oncolytics' plan to advance its pancreatic cancer program into a pivotal study Data to be discussed during a key opinion leader webinar on November 14 th at 10 a.m. ET SAN DIEGO, Calif and CALGARY, AB , Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

News for Oncolytics Biotech, Inc. Stock (ONCY)